DUBLIN--(BUSINESS WIRE)--The "Multiple Myeloma Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
The global multiple myeloma drugs market grew at a CAGR of around 9% during 2014-2019. Looking forward, the publisher expects the market to witness moderate growth during the next five years.
Multiple myeloma, or Kahler's disease, refers to a form of blood cancer that primarily affects the plasma cells. Some of the most common types of multiple myeloma drugs include chemotherapeutic agents, corticosteroids and immunomodulatory agents. These pharmaceutical drugs aid in promoting bone healing, prevent hypercalcemia, bone fracture, spinal cord compression and anemia, while minimizing the need for chemotherapy. The chemotherapeutic agents include various anthracycline antibiotics and alkylating agents, such as melphalan, doxorubicin, vincristine and liposomal doxorubicin. The targeted therapy drugs include proteasome inhibitor, such as bortezomib, and various other compounds, including dexamethasone, prednisone and thalidomide.
Significant developments in the healthcare sector, along with the increasing prevalence of hematological cancer, is one of the key factors driving the growth of the market. Multiple myeloma is usually caused by specific genetic abnormalities, and the treatment of this disease involves drugs that modulate the immune system and aid in enhancing the efficiency of chemotherapies, radiation therapies, stem cell transplants and platelet transfusion.
Furthermore, rising consumer awareness regarding the benefits of biologic therapy drugs, which utilize the body's immune system to identify and attack the myeloma cells, is also providing a boost to the market growth. Additionally, various technological advancements, such as the development of microRNA therapeutics and nanomedicines for the treatment of multiple myeloma, is acting as another growth-inducing factor. These medicines are used to facilitate the delivery of macromolecular agents into the bone marrow and catalyze antitumor responses. Other factors, including the rising healthcare expenditures and extensive research and development (R&D) activities in the field of medical sciences, are projected to drive the market further.
Companies Mentioned
- Amgen Inc.
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company
- Genzyme Corporation (Sanofi-Aventis)
- Johnson & Johnson Services Inc.
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Pharma Mar S.A.
- Takeda Pharmaceutical Company Limited.
- Teva Pharmaceutical Industries Ltd.
Key Questions Answered in This Report:
- How has the global multiple myeloma drugs market performed so far and how will it perform in the coming years?
- What are the key regional markets?
- What is the breakup of the market based on the therapy?
- What is the breakup of the market based on the drug type?
- What is the breakup of the market based on the end-user?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global multiple myeloma drugs market and who are the key players?
- What is the degree of competition in the industry?
Key Topics Covered:
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Multiple Myeloma Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Market Forecast
6 Market Breakup by Therapy
6.1 Targeted Therapy
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Biologic Therapy
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Chemotherapy
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Drug Type
7.1 Immunomodulatory Drugs
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Proteasome Inhibitors
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Histone Deacetylase Inhibitors
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Monoclonal Antibody Drugs
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Steroids
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Others
7.6.1 Market Trends
7.6.2 Market Forecast
8 Market Breakup by End-User
8.1 Men
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Women
8.2.1 Market Trends
8.2.2 Market Forecast
9 Market Breakup by Distribution Channel
9.1 Hospital Pharmacies
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Retail Pharmacies
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Online Pharmacies
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Others
9.4.1 Market Trends
9.4.2 Market Forecast
10 Market Breakup by Region
10.1 North America
10.2 Asia Pacific
10.3 Europe
10.4 Latin America
10.5 Middle East and Africa
11 SWOT Analysis
12 Value Chain Analysis
13 Porters Five Forces Analysis
14 Price Indicators
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
For more information about this report visit https://www.researchandmarkets.com/r/8yriem
